GLUT1: A Novel Tool re fl Ecting Proliferative Activity of Lung Neuroendocrine Tumors

Conditions: Lung Tumor

Sex: All

Healthy volunteers: No

Enrollment: 36

Sponsor: Centre Hospitalier Universitaire, Amiens

Location: CHU Amiens-Picardie Amiens

Summary

Lung neuroendocrine tumor (LNT) represents approximately 20% of all lung cancers. The classification of LNT relies upon morphology. Recently, in the World Health Organization (WHO) classification, Ki-67 rate has been proposed for classi fication. It is, however, known that Ki-67 count has a poor interlaboratory reproducibly. For that reason, our team has looked for a new biomarker. GLUT1 protein a facilitative glucose transporter protein which has ubiquitous expression in mammalian. GLUT1 is overexpressed in many human cancers. But, no study has evaluated the GLUT1 staining as an aid diagnosis in LNT. The team have assessed the GLUT1 immunohistochemical staining in 36 LNT and to assess its diagnostic value.

Eligibility Criteria

Inclusion Criteria: * Patients with neuroendocrine tumors Exclusion Criteria: * Patients without neuroendocrine tumors

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT03645915). StuddyBuddy aggregates publicly available trial information.